MammaPrint BluePrint illuminating tumor biology

Optimize Endocrine Therapy Duration in women with HR+/HER2-negative early breast cancer

NSABP-B42, IDEAL, and STO-3 demonstrate the ability of MammaPrint to identify a patient that:

>May REDUCE ET to <5 years in the event of intolerance1,2 (MammaPrint UltraLow Risk)

> Show benefit from 10 years of EET3,4 (MammaPrint Low Risk)

MammaPrint Index

MammaPrint UltraLow Risk patients may consider <5 years of endocrine therapy

MammaPrint UltraLow Risk patients may consider <5 years of endocrine therapy1,2

The STO-3 Trial demonstrated that MammaPrint UltraLow LN0 postmenopausal patients have excellent 20-year BCSS with only 2 years of ET, and can therefore help prevent potential overtreatment and enable excellent outcomes with less toxic effects.1

*MammaPrint UltraLow is included in the 2023 NCCN Guidelines®: ‘Gene Expression Assays for Consideration of Adjuvant Systemic Therapy’ Visit www.nccn.org to learn more

MammaPrint predicts benefit from extended endocrine therapy in postmenopausal Low Risk patients

MammaPrint predicts benefit from EET in postmenopausal Low Risk patients 3,4

Together, the prospective, randomized NSABP B-42 and IDEAL trials demonstrate Level 1B evidence that patients with MammaPrint Low Risk benefit from extended endocrine therapy.

Discuss the data with your local Agendia MOS & MSL

Request Data Review / Additional Data:
* indicates required
Select the data you would like to learn more about